Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

被引：0

作者：

Younes, Anas ^{[1
]}

Gordon, Leo ^{[2
]}

Kim, Stella

Romaguera, Jorge

Copeland, Amanda R. ^{[3
]}

Farial, Silvana de Castro

Kwak, Larry ^{[1
]}

Fayad, Luis

Hagemeister, Frederick

Fanale, Michelle

Lambert, John ^{[4
]}

Bagulho, Teresa ^{[5
]}

Morariu-Zamfir, Rodica ^{[6
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[2] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[4] ImmunoGen Inc, Res & Dev, Waltham, MA USA

[5] Sanofi Aventis, Bridgewater, NJ USA

[6] Sanofi Aventis, Bridgewatere, NJ USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：243 / 243

页数：1